Lazard Asset Management
LYEL icon

Lazard Asset Management’s Lyell Immunopharma LYEL Stock Holding History

Lazard Asset Management’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-9
Closed – – 2452
2024
Q4 		$0 Hold
9
– – ﹤0.01% 2429
2024
Q3 		$0 Sell
9
-17
-65% -$500 ﹤0.01% 2379
2024
Q2 		$0 Sell
26
-370
-93% -$17.6K ﹤0.01% 2353
2024
Q1 		$17K Sell
396
-224
-36% -$9.59K ﹤0.01% 1853
2023
Q4 		$23K Buy
620
+325
+110% +$11.7K ﹤0.01% 2042
2023
Q3 		$8K Buy
295
+11
+4% +$522 ﹤0.01% 2157
2023
Q2 		$17K Sell
284
-1,043
-79% -$57.7K ﹤0.01% 2126
2023
Q1 		$62K Buy
1,327
+914
+221% +$48.9K ﹤0.01% 1728
2022
Q4 		$28K Hold
413
– – ﹤0.01% 2056
2022
Q3 		$60K Buy
+413
New +$55.9K ﹤0.01% 1712

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Lazard Asset Management's LYEL Position: Q1 2025 in Review

Lazard Asset Management sold out of Lyell Immunopharma (LYEL) in Q1 2025, closing a stake of 9 shares.

Lazard Asset Management first reported a position in LYEL in Q3 2022 and held it in 10 quarters. The position peaked at $62K in Q1 2023. 112 funds tracked by Wall St. Rank hold LYEL as of Q1 2025.

  • Lazard Asset Management reported no remaining Lyell Immunopharma position as of Q1 2025 after selling out during the quarter.
  • Lazard Asset Management sold 9 Lyell Immunopharma shares in Q1 2025.
  • Lazard Asset Management first reported a position in Lyell Immunopharma in Q3 2022 and held it in 10 quarters.
  • Lazard Asset Management's Lyell Immunopharma position peaked at $62K in Q1 2023.
  • 112 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2025.

Based on Lazard Asset Management's 13F filing for Q1 2025, filed 15 May 2025.